Pharmaceutical

Coherus divests Udenyca franchise to Intas for up to $558.4m

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

Apr 16, 2025 - 06:00
Coherus divests Udenyca franchise to Intas for up to $558.4m
Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.
Read the original article

Tags:

Previous Article

ESCMID Global 2025: Climate-informed infectious disease risk management

Next Article

How collaborative partnerships are driving progress in transformative cell and g...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Signal: Novo Nordisk sues more Florida pharmacies in battle against fake semaglutide

Signal: Novo Nordisk sues more Florida pharmacies in ba...

Dec 2, 2023

Opinion: A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases

Opinion: A seemingly small semantic issue is a major ro...

Jun 28, 2023

FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on

FDA budget battles, prisons’ sobering Covid response & ...

May 23, 2023